Effects of antipsychotics, antidepressants and mood stabilizers on risk for physical diseases in people with schizophrenia, depression and bipolar disorder

World Psychiatry

Volumn 14, Issue 2, 2015, Pages 119-136

  Correll, Christoph U ^a,b,c,d   Detraux, Johan ^e   De Lepeleire, Jan ^e   De Hert, Marc ^e  

^a ZUCKER HILLSIDE HOSPITAL   (United States)

^b DONALD AND BARBARA ZUCKER SCHOOL OF MEDICINE AT HOFSTRA NORTHWELL   (United States)

^c FEINSTEIN INSTITUTE FOR MEDICAL RESEARCH   (United States)

^d ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^e UNIVERSITY OF LEUVEN   (Belgium)

Author keywords

antidepressants; antipsychotics; bipolar disorder; cardiovascular; depression; endocrine; gastrointestinal; metabolic; mood stabilizers; Physical illness; respiratory; schizophrenia

Indexed keywords

AMFEBUTAMONE; ANTIDEPRESSANT AGENT; ARIPIPRAZOLE; CARBAMAZEPINE; CLOZAPINE; HALOPERIDOL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LAMOTRIGINE; LITHIUM; LOW DENSITY LIPOPROTEIN CHOLESTEROL; LURASIDONE; MIRTAZAPINE; MOOD STABILIZER; NEUROLEPTIC AGENT; OLANZAPINE; PAROXETINE; SEROTONIN UPTAKE INHIBITOR; SERTINDOLE; THIORIDAZINE; THYROTROPIN; TRIACYLGLYCEROL; TRICYCLIC ANTIDEPRESSANT AGENT; VALPROIC ACID; VASOPRESSIN; VENLAFAXINE; ZIPRASIDONE;

AGRANULOCYTOSIS; ARTICLE; BIPOLAR DISORDER; BODY MASS; BREAST CANCER; CARDIOVASCULAR DISEASE; CEREBROVASCULAR ACCIDENT; CHOLESTEROL BLOOD LEVEL; CONSTIPATION; DEPRESSION; DIABETES MELLITUS; DIABETIC KETOACIDOSIS; DISEASE ASSOCIATION; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; DYSLIPIDEMIA; ENDOCRINE DISEASE; FRACTURE; GASTROINTESTINAL DISEASE; HEMATOLOGIC DISEASE; HIGH RISK PATIENT; HUMAN; HYPERTENSION; HYPONATREMIA; INAPPROPRIATE VASOPRESSIN SECRETION; ISCHEMIC HEART DISEASE; KIDNEY DISEASE; LEUKOPENIA; LIVER DYSFUNCTION; METABOLIC DISORDER; MORBIDITY; MORTALITY; MOTOR DYSFUNCTION; MUSCULOSKELETAL DISEASE; MYOCARDITIS; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; NUTRITIONAL DISORDER; OBESITY; OSTEOPOROSIS; OUTCOME ASSESSMENT; PHYSICAL CAPACITY; PHYSICAL DISEASE; PNEUMONIA; POLYPHARMACY; PRIORITY JOURNAL; PROLACTINOMA; QT PROLONGATION; RESPIRATORY TRACT DISEASE; RISK ASSESSMENT; SCHIZOPHRENIA; SEIZURE; SUDDEN CARDIAC DEATH; SYSTEMATIC REVIEW; THROMBOCYTOPENIA; THYROID DISEASE; THYROTROPIN BLOOD LEVEL; TRIACYLGLYCEROL BLOOD LEVEL; VASOPRESSIN RELEASE; VULNERABLE POPULATION; WEIGHT CHANGE;

EID: 84930444696     PISSN: 17238617     EISSN: 20515545     Source Type: Journal    
DOI: 10.1002/wps.20204     Document Type: Article

References (284)

1. Brown S, Kim M, Mitchell C, et al., Twenty-five year mortality of a community cohort with schizophrenia. Br J Psychiatry 2010; 196: 116-21.
2. Roshanaei-Moghaddam B, Katon W,. Premature mortality from general medical illnesses among persons with bipolar disorder: a review. Psychiatr Serv 2009; 60: 147-56.
3. Laursen TM,. Life expectancy among persons with schizophrenia or bipolar affective disorder. Schizophr Res 2011; 131: 101-4.
4. Tiihonen J, Lönnqvist J, Wahlbeck K, et al., 11-year follow-up of mortality in patients with schizophrenia: a population-based cohort study (FIN11 study). Lancet 2009; 374: 620-7.
5. Miller C, Bauer MS,. Excess mortality in bipolar disorders. Curr Psychiatry Rep 2014; 16: 499.
6. Ringen PA, Engh JA, Birkenaes AB, et al., Increased mortality in schizophrenia due to cardiovascular disease-a non-systematic review of epidemiology, possible causes, and interventions. Front Psychiatry 2014; 5: 137.
7. Crump C, Sundquist K, Winkleby MA, et al., Comorbidities and mortality in bipolar disorder: a Swedish national cohort study. JAMA Psychiatry 2013; 70: 931-9.
8. Laursen TM, Munk-Olsen T, Vestergaard M,. Life expectancy and cardiovascular mortality in persons with schizophrenia. Curr Opin Psychiatry 2012; 25: 83-8.
9. Chesney E, Goodwin GM, Fazel S,. Risks of all-cause and suicide mortality in mental disorders: a meta-review. World Psychiatry 2014; 13: 153-60.
10. Holt RI, Mitchell AJ,. Diabetes mellitus and severe mental illness: mechanisms and clinical implications. Nat Rev Endocrinol 2015; 11: 79-89.
11. De Hert M, Correll CU, Bobes J, et al., Physical illness in patients with severe mental disorders. I. Prevalence, impact of medications and disparities in health care. World Psychiatry 2011; 10: 52-77.
12. Gracious BL, Cook SR, Meyer AE, et al., Prevalence of overweight and obesity in adolescents with severe mental illness: a cross-sectional chart review. J Clin Psychiatry 2010; 71: 949-54.
13. Luppino FS, de Wit LM, Bouvy PF, et al., Overweight, obesity, and depression: a systematic review and meta-analysis of longitudinal studies. Arch Gen Psychiatry 2010; 67: 220-9.
14. McElroy SL, Keck PE, Jr,. Obesity in bipolar disorder: an overview. Curr Psychiatry Rep 2012; 14: 650-8.
15. Cerimele JM, Katon WJ,. Associations between health risk behaviors and symptoms of schizophrenia and bipolar disorder: a systematic review. Gen Hosp Psychiatry 2013; 35: 16-22.
16. Vancampfort D, Wampers M, Mitchell AJ, et al., A meta-analysis of cardio-metabolic abnormalities in drug naïve, first-episode and multi-episode patients with schizophrenia versus general population controls. World Psychiatry 2013; 12: 240-50.
17. Mitchell AJ, Vancampfort D, Sweers K, et al., Prevalence of metabolic syndrome and metabolic abnormalities in schizophrenia and related disorders-a systematic review and meta-analysis. Schizophr Bull 2013; 39: 306-18.
18. Britvic D, Maric NP, Doknic M, et al., Metabolic issues in psychotic disorders with the focus on first-episode patients: a review. Psychiatr Danub 2013; 25: 410-5.
19. Goldstein BI, Liu SM, Zivkovic N, et al., The burden of obesity among adults with bipolar disorder in the United States. Bipolar Disord 2011; 13: 387-95.
20. McElroy SL, Keck PE, Jr,. Metabolic syndrome in bipolar disorder: a review with a focus on bipolar depression. J Clin Psychiatry 2014; 75: 46-61.
21. Subramaniam M, Lam M, Guo ME, et al., Body mass index, obesity, and psychopathology in patients with schizophrenia. J Clin Psychopharmacol 2014; 34: 40-6.
22. Vancampfort D, Correll CU, Wampers M, et al., Metabolic syndrome and metabolic abnormalities in patients with major depressive disorder: a meta-analysis of prevalences and moderating variables. Psychol Med (in press).
23. Hasnain M, Vieweg WV, Hollett B,. Weight gain and glucose dysregulation with second-generation antipsychotics and antidepressants: a review for primary care physicians. Postgrad Med 2012; 124: 154-67.
24. Bak M, Fransen A, Janssen J, et al., Almost all antipsychotics result in weight gain: a meta-analysis. PLoS One 2014; 9: e94112.
25. Leucht S, Corves C, Arbter D, et al., Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. Lancet 2009; 373: 31-41.
26. Parsons B, Allison DB, Loebel A, et al., Weight effects associated with antipsychotics: a comprehensive database analysis. Schizophr Res 2009; 110: 103-10.
27. Rummel-Kluge C, Komossa K, Schwarz S, et al., Head-to-head comparisons of metabolic side effects of second generation antipsychotics in the treatment of schizophrenia: a systematic review and meta-analysis. Schizophr Res 2010; 123: 225-33.
28. Fiedorowicz JG, Miller DD, Bishop JR, et al., Systematic review and meta-analysis of pharmacological interventions for weight gain from antipsychotics and mood stabilizers. Curr Psychiatry Rev 2012; 8: 25-36.
29. De Hert M, Yu W, Detraux J, et al., Body weight and metabolic adverse effects of asenapine, iloperidone, lurasidone and paliperidone in the treatment of schizophrenia and bipolar disorder: a systematic review and exploratory meta-analysis. CNS Drugs 2012; 26: 733-59.
30. De Hert M, Detraux J, van Winkel R, et al., Metabolic and cardiovascular adverse effects associated with antipsychotic drugs. Nat Rev Endocrinol 2011; 8: 114-26.
31. Das C, Mendez G, Jagasia S, et al., Second-generation antipsychotic use in schizophrenia and associated weight gain: a critical review and meta-analysis of behavioral and pharmacologic treatments. Ann Clin Psychiatry 2012; 24: 225-39.
32. Leucht S, Cipriani A, Spineli L, et al., Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. Lancet 2013; 382: 951-62.
33. Yogaratnam J, Biswas N, Vadivel R, et al., Metabolic complications of schizophrenia and antipsychotic medications-an updated review. East Asian Arch Psychiatry 2013; 23: 21-8.
34. Maayan L, Correll CU,. Weight gain and metabolic risks associated with antipsychotic medications in children and adolescents. J Child Adolesc Psychopharmacol 2011; 21: 517-35.
35. O'Donoghue B, Schäfer MR, Becker J, et al., Metabolic changes in first-episode early-onset schizophrenia with second-generation antipsychotics. Early Interv Psychiatry 2014; 8: 276-80.
36. De Hert M, Dobbelaere M, Sheridan EM, et al., Metabolic and endocrine adverse effects of second-generation antipsychotics in children and adolescents: a systematic review of randomized, placebo controlled trials and guidelines for clinical practice. Eur Psychiatry 2011; 26: 144-58.
37. Patel JK, Buckley PF, Woolson S, et al., Metabolic profiles of second-generation antipsychotics in early psychosis: findings from the CAFÉ study. Schizophr Res 2009; 111: 9-16.
38. Pérez-Iglesias R, Martínez-García O, Pardo-Garcia G, et al., Course of weight gain and metabolic abnormalities in first treated episode of psychosis: the first year is a critical period for development of cardiovascular risk factors. Int J Neuropsychopharmacol 2014; 17: 41-51.
39. Deng C,. Effects of antipsychotic medications on appetite, weight, and insulin resistance. Endocrinol Metab Clin North Am 2013; 42: 545-63.
40. McKnight RF, Adida M, Budge K, et al., Lithium toxicity profile: a systematic review and meta-analysis. Lancet 2012; 379: 721-8.
41. Blumenthal SR, Castro VM, Clements CC, et al., An electronic health records study of long-term weight gain following antidepressant use. JAMA Psychiatry 2014; 71: 889-96.
42. Ballon JS, Pajvani U, Freyberg Z, et al., Molecular pathophysiology of metabolic effects of antipsychotic medications. Trends Endocrinol Metab 2014; 25: 593-600.
43. Lopresti AL, Drummond PD,. Obesity and psychiatric disorders: commonalities in dysregulated biological pathways and their implications for treatment. Prog Neuropsychopharmacol Biol Psychiatry 2013; 45: 92-9.
44. Reynolds GP, Kirk SL,. Metabolic side effects of antipsychotic drug treatment-pharmacological mechanisms. Pharmacol Ther 2010; 125: 169-79.
45. Serretti A, Mandelli L,. Antidepressants and body weight: a comprehensive review and meta-analysis. J Clin Psychiatry 2010; 71: 1259-72.
46. Reynolds GP,. Pharmacogenetic aspects of antipsychotic drug-induced weight gain-a critical review. Clin Psychopharmacol Neurosci 2012; 10: 71-7.
47. Vancampfort D, Vansteelandt K, Correll CU, et al., Metabolic syndrome and metabolic abnormalities in bipolar disorder: a meta-analysis of prevalence rates and moderators. Am J Psychiatry 2013; 170: 265-74.
48. McIntyre RS, Soczynska JK, Konarski JZ, et al., The effect of antidepressants on lipid homeostasis: a cardiac safety concern? Expert Opin Drug Saf 2006; 5: 523-37.
49. McIntyre RS, McElroy SL, Eudicone JM, et al., A 52-week, double-blind evaluation of the metabolic effects of aripiprazole and lithium in bipolar I disorder. Prim Care Companion CNS Disord 2011; 13 (6).
50. Ezzaher A, Haj Mouhamed D, Mechri A, et al., Thyroid function and lipid profile in bipolar I patients. Asian J Psychiatry 2011; 4: 139-43.
51. Casey DE, Daniel DG, Wassef AA, et al., Effect of divalproex combined with olanzapine or risperidone in patients with an acute exacerbation of schizophrenia. Neuropsychopharmacology 2003; 28: 82-92.
52. Elmslie JL, Porter RJ, Joyce PR, et al., Comparison of insulin resistance, metabolic syndrome and adiponectin in overweight bipolar patients taking sodium valproate and controls. Aust N Zeal J Psychiatry 2009; 43: 53-60.
53. Chang HH, Yang YK, Gean PW, et al., The role of valproate in metabolic disturbances in bipolar disorder patients. J Affect Disord 2010; 124: 319-23.
54. Calkin CV, Gardner DM, Ransom T, Alda M,. The relationship between bipolar disorder and type 2 diabetes: more than just co-morbid disorders. Ann Med 2013; 45: 171-81.
55. Bai YM, Su TP, Chen MH, et al., Risk of developing diabetes mellitus and hyperlipidemia among patients with bipolar disorder, major depressive disorder, and schizophrenia: a 10-year nationwide population-based prospective cohort study. J Affect Disord 2013; 150: 57-62.
56. Mitchell AJ, Vancampfort D, De Herdt A, et al., Is the prevalence of metabolic syndrome and metabolic abnormalities increased in early schizophrenia?. A comparative meta-analysis of first episode, untreated and treated patients. Schizophr Bull 2013; 39: 295-305.
57. Chien IC, Wu EL, Lin CH, et al., Prevalence of diabetes in patients with major depressive disorder: a population-based study. Compr Psychiatry 2012; 53: 569-75.
58. Sernyak MJ, Leslie DL, Alarcon RD, et al., Association of diabetes mellitus with use of atypical neuroleptics in the treatment of schizophrenia. Am J Psychiatry 2002; 159: 561-6.
59. McEvoy JP, Meyer JM, Goff DC, et al., Prevalence of the metabolic syndrome in patients with schizophrenia: baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial and comparison with national estimates from NHANES III. Schizophr Res 2005; 80: 19-32.
60. Smith M, Hokins D, Peveler R, et al., First- versus second-generation antipsychotics and risk for diabetes in schizophrenia: systematic review and meta-analysis. Br J Psychiatry 2008; 192: 406-11.
61. Hartling L, Abou-Setta AM, Dursun S, et al., Antipsychotics in adults with schizophrenia: comparative effectiveness of first-generation versus second-generation medications: a systematic review and meta-analysis. Ann Intern Med 2012; 157: 498-511.
62. Yood MU, DeLorenze G, Quesenberry CP, Jr,. et al. The incidence of diabetes in atypical antipsychotic users differs according to agent-results from a multisite epidemiologic study. Pharmacoepidemiol Drug Saf 2009; 18: 791-9.
63. Nielsen J, Skadhede S, Correll CU,. Antipsychotics associated with the development of type 2 diabetes in antipsychotic-naïve schizophrenia patients. Neuropsychopharmacology 2010; 35: 1997-2004.
64. Fleischhacker WW, Siu CO, Bodén R, et al., Metabolic risk factors in first-episode schizophrenia: baseline prevalence and course analysed from the European First-Episode Schizophrenia Trial. Int J Neuropsychopharmacol 2013; 16: 987-95.
65. Samaras K, Correll CU, Mitchell AJ, et al., Diabetes risk potentially underestimated in youth and children receiving antipsychotics. JAMA Psychiatry 2014; 71: 209-10.
66. Bobo WV, Cooper WO, Stein CM, et al., Antipsychotics and the risk of type 2 diabetes mellitus in children and youth. JAMA Psychiatry 2013; 70: 1067-75.
67. Weston-Green K, Huang XF, Deng C,. Second generation antipsychotic-induced type 2 diabetes: a role for the muscarinic M3 receptor. CNS Drugs 2013; 27: 1069-80.
68. Deuschle M,. Effects of antidepressants on glucose metabolism and diabetes mellitus type 2 in adults. Curr Opin Psychiatry 2013; 26: 60-5.
69. Kivimäki M, Batty GD,. Antidepressant drug use and future diabetes risk. Diabetologia 2012; 55: 10-2.
70. Whiskey E, Taylor D,. A review of the adverse effects and safety of noradrenergic antidepressants. J Psychopharmacol 2013; 27: 732-9.
71. Barnard K, Peveler RC, Holt RI,. Antidepressant medication as a risk factor for type 2 diabetes and impaired glucose regulation: systematic review. Diabetes Care 2013; 36: 3337-45.
72. Yoon JM, Cho EG, Lee HK, et al., Antidepressant use and diabetes mellitus risk: a meta-analysis. Korean J Fam Med 2013; 34: 228-40.
73. Ma Y, Balasubramanian R, Pagoto SL, et al., Relations of depressive symptoms and antidepressant use to body mass index and selected biomarkers for diabetes and cardiovascular disease. Am J Public Health 2013; 103: e34-43.
74. Andersohn F, Schade R, Suissa S, et al., Long-term use of antidepressants for depressive disorders and the risk of diabetes mellitus. Am J Psychiatry 2009; 166: 591-8.
75. Kivimäki M, Hamer M, Batty GD, et al., Antidepressant medication use, weight gain, and risk of type 2 diabetes: a population-based study. Diabetes Care 2010; 33: 2611-6.
76. Kivimäki M, Batty GD, Jokela M, et al., Antidepressant medication use and risk of hyperglycemia and diabetes mellitus: a noncausal association? Biol Psychiatry 2011; 70: 978-84.
77. Lopez-Yarto M, Ruiz-Mirazo E, Holloway AC, et al., Do psychiatric medications, especially antidepressants, adversely impact maternal metabolic outcomes? J Affect Disord 2012; 141: 120-9.
78. Bhattacharjee S, Bhattacharya R, Kelley GA, et al., Antidepressant use and new-onset diabetes: a systematic review and meta-analysis. Diabetes Metab Res Rev 2013; 29: 273-84.
79. Wilkins TL, Sambamoorthi U,. Antidepressant use, depression, lifestyle factors, and new-onset diabetes. Int Clin Psychopharmacol 2011; 26: 159-68.
80. Brown LC, Majumdar SR, Johnson JA,. Type of antidepressant therapy and risk of type 2 diabetes in people with depression. Diabetes Res Clin Pract 2008; 79: 61-7.
81. Andersohn F, Schade R, Suissa S, et al., Long-term use of antidepressants for depressive disorders and the risk of diabetes mellitus. Am J Psychiatry 2009; 166: 591-8.
82. Rubin RR, Ma Y, Marrero DG, et al., Elevated depression symptoms, antidepressant medicine use, and risk of developing diabetes during the diabetes prevention program. Diabetes Care 2008; 31: 420-6.
83. Belcastro V, D'Egidio C, Striano P, et al., Metabolic and endocrine effects of valproic acid chronic treatment. Epilepsy Res 2013; 107: 1-8.
84. Jin H, Meyer JM, Jeste DV,. Atypical antipsychotics and glucose dysregulation: a systematic review. Schizophr Res 2004; 71: 195-212.
85. Guenette MD, Hahn M, Cohn TA, et al., Atypical antipsychotics and diabetic ketoacidosis: a review. Psychopharmacology 2013; 226: 1-12.
86. Cohen D, Correll CU,. Second-generation antipsychotic-associated diabetes mellitus and diabetic ketoacidosis: mechanisms, predictors, and screening need. J Clin Psychiatry 2009; 70: 765-6.
87. Baker RA, Pikalov A, Tran QV, et al., Atypical antipsychotic drugs and diabetes mellitus in the US Food and Drug Administration Adverse Event Database: a systematic Bayesian signal detection analysis. Psychopharmacol Bull 2009; 42: 11-31.
88. Kelly DL, Conley RR,. Thyroid function in treatment-resistant schizophrenia patients treated with quetiapine, risperidone, or fluphenazine. J Clin Psychiatry 2005; 66: 80-4.
89. Meulendijks D, Mannesse CK, Jansen PA, et al., Antipsychotic-induced hyponatraemia: a systematic review of the published evidence. Drug Saf 2010; 33: 101-14.
90. Mannesse CK, van Puijenbroek EP, Jansen PA, et al., Hyponatraemia as an adverse drug reaction of antipsychotic drugs: a case-control study in VigiBase. Drug Saf 2010; 33: 569-78.
91. Coupland CA, Dhiman P, Barton G, et al., A study of the safety and harms of antidepressant drugs for older people: a cohort study using a large primary care database. Health Technol Assess 2011; 15: 1-202.
92. De Picker L, Van Den Eede F, Dumont G, et al., Antidepressants and the risk of hyponatremia: a class-by-class review of literature. Psychosomatics 2014; 55: 536-47.
93. Correll CU,. From receptor pharmacology to improved outcomes: individualising the selection, dosing, and switching of antipsychotics. Eur Psychiatry 2010; 25 (Suppl. 2): S12-21.
94. Stahl SM, Grady MM, Moret C, et al., SNRIs: their pharmacology, clinical efficacy, and tolerability in comparison with other classes of antidepressants. CNS Spectr 2005; 10: 732-47.
95. Watanabe N, Omori IM, Nakagawa A, et al., Safety reporting and adverse-event profile of mirtazapine described in randomized controlled trials in comparison with other classes of antidepressants in the acute-phase treatment of adults with depression: systematic review and meta-analysis. CNS Drugs 2010; 24: 35-53.
96. Bresee LC, Majumdar SR, Patten SB, et al., Prevalence of cardiovascular risk factors and disease in people with schizophrenia: a population-based study. Schizophr Res 2010; 117: 75-82.
97. Weiner M, Warren L, Fiedorowicz JG,. Cardiovascular morbidity and mortality in bipolar disorder. Ann Clin Psychiatry 2011; 23: 40-7.
98. Callaghan RC, Khizar A,. The incidence of cardiovascular morbidity among patients with bipolar disorder: a population-based longitudinal study in Ontario, Canada. J Affect Disord 2010; 122: 118-23.
99. Fan Z, Wu Y, Shen J, et al., Schizophrenia and the risk of cardiovascular diseases: a meta-analysis of thirteen cohort studies. J Psychiatr Res 2013; 47: 1549-56.
100. Lemogne C, Nabi H, Melchior M, et al., Mortality associated with depression as compared with other severe mental disorders: a 20-year follow-up study of the GAZEL cohort. J Psychiatr Res 2013; 47: 851-7.
101. Sweeting J, Duflou J, Semsarian C,. Postmortem analysis of cardiovascular deaths in schizophrenia: a 10-year review. Schizophr Res 2013; 150: 398-403.
102. Kisely S, Preston N, Xiao J, et al., Reducing all-cause mortality among patients with psychiatric disorders: a population-based study. CMAJ 2013; 185: E50-6.
103. Acharya T, Acharya S, Tringali S, et al., Association of antidepressant and atypical antipsychotic use with cardiovascular events and mortality in a veteran population. Pharmacotherapy 2013; 33: 1053-61.
104. Hsieh PH, Hsiao FY, Gau SS, et al., Use of antipsychotics and risk of cerebrovascular events in schizophrenic patients: a nested case-control study. J Clin Psychopharmacol 2013; 33: 299-305.
105. Huybrechts KF, Schneeweiss S, Gerhard T, et al., Comparative safety of antipsychotic medications in nursing home residents. J Am Geriatr Soc 2012; 60: 420-9.
106. Sacchetti E, Turrina C, Valsecchi P,. Cerebrovascular accidents in elderly people treated with antipsychotic drugs: a systematic review. Drug Saf 2010; 33: 273-88.
107. Jackson JW, Schneeweiss S, VanderWeele TJ, et al., Quantifying the role of adverse events in the mortality difference between first and second-generation antipsychotics in older adults: systematic review and meta-synthesis. PLoS One 2014; 9: e105376.
108. Brauer R, Douglas I, Smeeth L,. The association between antipsychotic agents and the risk of myocardial infarction: a systematic review. Br J Clin Pharmacol 2011; 72: 871-8.
109. Lin ST, Chen CC, Tsang HY, et al., Association between antipsychotic use and risk of acute myocardial infarction: a nationwide case-crossover study. Circulation 2014; 130: 235-43.
110. Pariente A, Fourrier-Réglat A, Ducruet T, et al., Antipsychotic use and myocardial infarction in older patients with treated dementia. Arch Intern Med 2012; 172: 648-53.
111. Brauer R, Smeeth L, Anaya-Izquierdo K, et al., Antipsychotic drugs and risks of myocardial infarction: a self-controlled case series study. Eur Heart J (in press).
112. Wu S-I, Kao K-L, Chen S-C, et al., Antipsychotic exposure prior to acute myocardial infarction in patients with serious mental illness. Acta Psychiatr Scand 2015; 131: 213-22.
113. Darbà J, Kaskens L, Aranda P, et al., A simulation model to estimate 10-year risk of coronary heart disease events in patients with schizophrenia spectrum disorders treated with second-generation antipsychotic drugs. Ann Clin Psychiatry 2013; 25: 17-26.
114. Citrome L, Collins JM, Nordstrom BL, et al., Incidence of cardiovascular outcomes and diabetes mellitus among users of second-generation antipsychotics. J Clin Psychiatry 2013; 74: 1199-206.
115. Stroup TS, Byerly MJ, Nasrallah HA, et al., Effects of switching from olanzapine, quetiapine, and risperidone to aripiprazole on 10-year coronary heart disease risk and metabolic syndrome status: results from a randomized controlled trial. Schizophr Res 2013; 146: 190-5.
116. Kiviniemi M, Suvisaari J, Koivumaa-Honkanen H, et al., Antipsychotics and mortality in first-onset schizophrenia: prospective Finnish register study with 5-year follow-up. Schizophr Res 2013; 150: 274-80.
117. Pasternak B, Svanström H, Ranthe MF, et al., Atypical antipsychotics olanzapine, quetiapine, and risperidone and risk of acute major cardiovascular events in young and middle-aged adults: a nationwide register-based cohort study in Denmark. CNS Drugs 2014; 28: 963-73.
118. Correll CU, Joffe BI, Rosen LM, et al., Cardiovascular and cerebrovascular risk factors and events associated with second-generation antipsychotic compared to antidepressant use in a non-elderly adult sample: results from a claims-based inception cohort study. World Psychiatry 2015; 14: 55-62.
119. Ratliff JC, Palmese LB, Reutenauer EL, et al., Obese schizophrenia spectrum patients have significantly higher 10-year general cardiovascular risk and vascular ages than obese individuals without severe mental illness. Psychosomatics 2013; 54: 67-73.
120. Scigliano G, Ronchetti G,. Antipsychotic-induced metabolic and cardiovascular side effects in schizophrenia: a novel mechanistic hypothesis. CNS Drugs 2013; 27: 249-57.
121. García-Tornadú I, Ornstei A, Chamson-Reig A, et al., Disruption of the dopamine D2 receptor impairs insulin secretion and causes glusose intolerance. Endocrinology 2010; 151: 1441-50.
122. Mago R, Tripathi N, Andrade C,. Cardiovascular adverse effects of newer antidepressants. Expert Rev Neurother 2014; 14: 539-51.
123. Sowden GL, Huffman JC,. The impact of mental illness on cardiac outcomes: a review for the cardiologist. Int J Cardiol 2009; 132: 30-7.
124. Khawaja IS, Westermeyer JJ, Gajwani P, et al., Depression and coronary artery disease: the association, mechanisms, and therapeutic implications. Psychiatry 2009; 6: 38-51.
125. Beach SR, Kostis WJ, Celano CM, et al., Meta-analysis of selective serotonin reuptake inhibitor-associated QTc prolongation. J Clin Psychiatry 2014; 75: e441-9.
126. Beach SR, Celano CM, Noseworthy PA, et al., QTc prolongation, torsades de pointes, and psychotropic medications. Psychosomatics 2013; 54: 1-13.
127. Nielsen J, Correll CU, Manu P, et al., Termination of clozapine treatment due to medical reasons: when is it warranted and how can it be avoided? J Clin Psychiatry 2013; 74: 603-13.
128. Ronaldson KJ, Fitzgerald PB, Taylor AJ, et al., Clinical course and analysis of ten fatal cases of clozapine-induced myocarditis and comparison with 66 surviving cases. Schizophr Res 2011; 128: 161-5.
129. Manu P, Sarpal D, Muir O, et al., When can patients with potentially life-threatening adverse effects be rechallenged with clozapine? A systematic review of the published literature. Schizophr Res 2012; 134: 180-6.
130. Ifteni P, Correll CU, Burtea V, et al., Sudden unexpected death in schizophrenia: autopsy findings in psychiatric inpatients. Schizophr Res 2014; 155: 72-6.
131. Blom MT, Cohen D, Seldenrijk A, et al., Brugada syndrome ECG is highly prevalent in schizophrenia. Circ Arrhythm Electrophysiol 2014; 7: 384-91.
132. Murray-Thomas T, Jones ME, Patel D, et al., Risk of mortality (including sudden cardiac death) and major cardiovascular events in atypical and typical antipsychotic users: a study with the general practice research database. Cardiovasc Psychiatry Neurol 2013; 2013: 247486.
133. Shah AA, Aftab A, Coverdale J,. QTc prolongation with antipsychotics: is routine ECG monitoring recommended? J Psychiatr Pract 2014; 20: 196-206.
134. Hasnain M, Vieweg WV,. QTc Interval prolongation and torsade de pointes associated with second-generation antipsychotics and antidepressants: a comprehensive review. CNS Drugs 2014; 28: 887-920.
135. Ray WA, Chung CP, Murray KT, et al., Atypical antipsychotic drugs and the risk of sudden cardiac death. N Engl J Med 2009; 360: 225-35.
136. Weeke P, Jensen A, Folke F, et al., Antipsychotics and associated risk of out-of-hospital cardiac arrest. Clin Pharmacol Ther 2014; 96: 490-7.
137. Leonard CE, Freeman CP, Newcomb CW, et al., Antipsychotics and the risks of sudden cardiac death and all-cause death: cohort studies in Medicaid and dually-eligible Medicaid-Medicare beneficiaries of five States. J Clin Exp Cardiol 2013; 10 (Suppl. 6): 1-9.
138. Pae CU, Wang SM, Lee SJ, et al., Antidepressant and QT interval prolongation, how should we look at this issue?. Focus on citalopram. Expert Opin Drug Saf 2014; 13: 197-205.
139. Alvarez PA, Pahissa J,. QT alterations in psychopharmacology: proven candidates and suspects. Curr Drug Saf 2010; 5: 97-104.
140. Raschi E, Poluzzi E, Godman B, et al., Torsadogenic risk of antipsychotics: combining adverse event reports with drug utilization data across Europe. PLoS One 2013; 8: e81208.
141. Poluzzi E, Raschi E, Koci A, et al., Antipsychotics and torsadogenic risk: signals emerging from the US FDA Adverse Event Reporting System database. Drug Saf 2013; 36: 467-79.
142. Kogut C, Crouse EB, Vieweg WV, et al., Selective serotonin reuptake inhibitors and torsade de pointes: new concepts and new directions derived from a systematic review of case reports. Ther Adv Drug Saf 2013; 4: 189-98.
143. Spina E, de Leon J,. Clinically relevant interactions between newer antidepressants and second-generation antipsychotics. Expert Opin Drug Metab Toxicol 2014; 10: 721-46.
144. Huertas-Vazquez A, Nelson CP, Guo X, et al., Novel loci associated with increased risk of sudden cardiac death in the context of coronary artery disease. PLoS One 2013; 8: e59905.
145. Healy D, Le Noury J, Harris M, et al., Mortality in schizophrenia and related psychoses: data from two cohorts, 1875-1924 and 1994-2010. BMJ Open 2012; 2: e001810.
146. Castagnini A, Foldager L, Bertelsen A,. Excess mortality of acute and transient psychotic disorders: comparison with bipolar affective disorder and schizophrenia. Acta Psychiatr Scand 2013; 128: 370-5.
147. Weber NS, Fisher JA, Cowan DN, et al., Psychiatric and general medical conditions comorbid with bipolar disorder in the National Hospital Discharge Survey. Psychiatr Serv 2011; 62: 1152-8.
148. Lawrence D, Kisely S, Pais J,. The epidemiology of excess mortality in people with mental illness. Can J Psychiatry 2010; 55: 752-60.
149. Shen HN, Lu CL, Yang HH,. Increased risks of acute organ dysfunction and mortality in intensive care unit patients with schizophrenia: a nationwide population-based study. Psychosom Med 2011; 73: 620-6.
150. Kuo CJ, Yang SY, Liao YT, et al., Second-generation antipsychotic medications and risk of pneumonia in schizophrenia. Schizophr Bull 2013; 39: 648-57.
151. Haddad PM,. Current use of second-generation antipsychotics may increase risk of pneumonia in people with schizophrenia. Evid Based Ment Health 2013; 16: 109.
152. Yang SY, Liao YT, Liu HC, et al., Antipsychotic drugs, mood stabilizers, and risk of pneumonia in bipolar disorder: a nationwide case-control study. J Clin Psychiatry 2013; 74: e79-86.
153. Trifirò G, Gambassi G, Sen EF, et al., Association of community-acquired pneumonia with antipsychotic drug use in elderly patients: a nested case-control study. Ann Intern Med 2010; 152: 418-25.
154. Trifirò G,. Antipsychotic drug use and community-acquired pneumonia. Curr Infect Dis Rep 2011; 13: 262-8.
155. Gau JT, Acharya U, Khan S, et al., Pharmacotherapy and the risk for community-acquired pneumonia. BMC Geriatr 2010; 10: 45.
156. Star K, Bate A, Meyboom RH, et al., Pneumonia following antipsychotic prescriptions in electronic health records: a patient safety concern? Br J Gen Pract 2010; 60: e385-94.
157. Pratt N, Roughead EE, Ramsay E, et al., Risk of hospitalization for hip fracture and pneumonia associated with antipsychotic prescribing in the elderly: a self-controlled case-series analysis in an Australian health care claims database. Drug Saf 2011; 34: 567-75.
158. Huybrechts KF, Rothman KJ, Silliman RA, et al., Risk of death and hospital admission for major medical events after initiation of psychotropic medications in older adults admitted to nursing homes. CMAJ 2011; 183: E411-9.
159. Marwick KF, Taylor M, Walker SW,. Antipsychotics and abnormal liver function tests: systematic review. Clin Neuropharmacol 2012; 35: 244-53.
160. Voican CS, Corruble E, Naveau S, et al., Antidepressant-induced liver injury: a review for clinicians. Am J Psychiatry 2014; 171: 404-15.
161. Stadlmann S, Portmann S, Tschopp S, et al., Venlafaxine-induced cholestatic hepatitis: case report and review of literature. Am J Surg Pathol 2012; 36: 1724-8.
162. Park SH, Ishino R,. Liver injury associated with antidepressants. Curr Drug Saf 2013; 8: 207-23.
163. Sedky K, Nazir R, Joshi A, et al., Which psychotropic medications induce hepatotoxicity? Gen Hosp Psychiatry 2012; 34: 53-61.
164. De Hert M, Hudyana H, Dockx L, et al., Second-generation antipsychotics and constipation: a review of the literature. Eur Psychiatry 2011; 26: 34-44.
165. Ozbilen M, Adams CE, Marley J,. Anticholinergic effects of oral antipsychotic drugs of typicals versus atypicals over medium- and long-term: systematic review and meta-analysis. Curr Med Chem 2012; 19: 5214-8.
166. Ozbilen M, Adams CE,. Systematic overview of Cochrane reviews for anticholinergic effects of antipsychotic drugs. J Clin Psychopharmacol 2009; 29: 141-6.
167. Andrès E, Zimmer J, Mecili M, et al., Clinical presentation and management of drug-induced agranulocytosis. Expert Rev Hematol 2011; 4: 143-51.
168. Schneider C, Corrigall R, Hayes D, et al., Systematic review of the efficacy and tolerability of clozapine in the treatment of youth with early onset schizophrenia. Eur Psychiatry 2014; 29: 1-10.
169. Kripalani M, Shawcross J, Reilly J, et al., Lithium and chronic kidney disease. BMJ 2009; 339: b2452.
170. Hasan A, Falkai P, Wobrock T, et al., World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, part 2: update 2012 on the long-term treatment of schizophrenia and management of antipsychotic-induced side effects. World J Biol Psychiatry 2013; 14: 2-44.
171. Shuman MD, Trigoboff E, Demler TL, et al., Exploring the potential effect of polypharmacy on the hematologic profiles of clozapine patients. J Psychiatr Pract 2014; 20: 50-8.
172. Vasudev K, Keown P, Gibb I, et al., Hematological effects of valproate in psychiatric patients: what are the risk factors? J Clin Psychopharmacol 2010; 30: 282-5.
173. Ji J, Sundquist K, Ning Y, et al., Incidence of cancer in patients with schizophrenia and their first-degree relatives: a population-based study in Sweden. Schizophr Bull 2013; 39: 527-36.
174. Anothaisintawee T, Wiratkapun C, Lerdsitthichai P, et al., Risk factors of breast cancer: a systematic review and meta-analysis. Asia Pac J Publ Health 2013; 25: 368-87.
175. Matsen CB, Neumayer LA,. Breast cancer: a review for the general surgeon. JAMA Surg 2013; 148: 971-9.
176. DeSantis C, Ma J, Bryan L, et al., Breast cancer statistics, 2013. CA Cancer J Clin 2014; 64: 52-62.
177. Zimbron J, Stahl D, Hutchinson G, et al., Pre-morbid fertility in psychosis: findings from the AESOP first episode study. Schizophr Res 2014; 156: 168-73.
178. Power RA, Kyaga S, Uher R, et al., Fecundity of patients with schizophrenia, autism, bipolar disorder, depression, anorexia nervosa, or substance abuse vs their unaffected siblings. JAMA Psychiatry 2013; 70: 22-30.
179. McGinty EE, Zhang Y, Guallar E, et al., Cancer incidence in a sample of Maryland residents with serious mental illness. Psychiatr Serv 2012; 63: 714-7.
180. Lin GM, Chen YJ, Kuo DJ, et al., Cancer incidence in patients with schizophrenia or bipolar disorder: a nationwide population-based study in Taiwan, 1997-2009. Schizophr Bull 2013; 39: 407-16.
181. Lin CY, Lane HY, Chen TT, et al., Inverse association between cancer risks and age in schizophrenic patients: a 12-year nationwide cohort study. Cancer Sci 2013; 104: 383-90.
182. Ajdacic-Gross V, Tschopp A, Bopp M, et al., Cancer comortality patterns in schizophrenia and psychotic disorders: a new methodological approach for unique databases. Int J Methods Psychiatr Res 2014; 23: 19-24.
183. Chou FH, Tsai KY, Su CY, et al., The incidence and relative risk factors for developing cancer among patients with schizophrenia: a nine-year follow-up study. Schizophr Res 2011; 129: 97-103.
184. Osborn DP, Limburg H, Walters K, et al., Relative incidence of common cancers in people with severe mental illness. Cohort study in the United Kingdom THIN primary care database. Schizophr Res 2013; 143: 44-9.
185. Catalá-Lõpez F, Suárez-Pinilla M, Suárez-Pinilla P, et al., Inverse and direct cancer comorbidity in people with central nervous system disorders: a meta-analysis of cancer incidence in 577,013 participants of 50 observational studies. Psychother Psychosom 2014; 83: 89-105.
186. De Hert M, Peuskens J, Sabbe T, et al., Relationship between prolactin, breast cancer risk and antipsychotics in patients with schizophrenia: a critical review. Acta Psychiatr Scand (in press).
187. Wang PS, Walker AM, Tsuang MT, et al., Dopamine antagonists and the development of breast cancer. Arch Gen Psychiatry 2002; 59: 1147-54.
188. Peuskens J, Pani L, Detraux J, et al., The effects of novel and newly approved antipsychotics on serum prolactin levels: a comprehensive review. CNS Drugs 2014; 28: 421-53.
189. Azoulay L, Yin H, Renoux C, et al., The use of atypical antipsychotics and the risk of breast cancer. Breast Cancer Res Treat 2011; 129: 541-8.
190. Fond G, Macgregor A, Attal J, et al., Antipsychotic drugs: pro-cancer or anti-cancer?. A systematic review. Med Hypotheses 2012; 79: 38-42.
191. Bielecka AM, Obuchowicz E,. Antidepressant drugs as a complementary therapeutic strategy in cancer. Exp Biol Med 2013; 238: 849-58.
192. Frick LR, Rapanelli M,. Antidepressants: influence on cancer and immunity? Life Sci 2013; 92: 525-32.
193. Yde CW, Clausen MP, Bennetzen MV, et al., The antipsychotic drug chlorpromazine enhances the cytotoxic effect of tamoxifen in tamoxifen-sensitive and tamoxifen-resistant human breast cancer cells. Anticancer Drugs 2009; 20: 723-35.
194. Huang L, Zhao S, Frasor JM, et al., An integrated bioinformatics approach identifies elevated cyclin E2 expression and E2F activity as distinct features of tamoxifen resistant breast tumors. PLoS One 2011; 6: e22274.
195. Rahman T, Clevenger CV, Kaklamani V, et al., Antipsychotic treatment in breast cancer patients. Am J Psychiatry 2014; 171: 616-21.
196. Coker F, Taylor D,. Antidepressant-induced hyperprolactinaemia: incidence, mechanisms and management. CNS Drugs 2010; 24: 563-74.
197. Madhusoodanan S, Parida S, Jimenez C,. Hyperprolactinemia associated with psychotropics-a review. Hum Psychopharmacol 2010; 25: 281-97.
198. Ashbury JE, Lévesque LE, Beck PA, et al., Selective serotonin reuptake inhibitor (SSRI) antidepressants, prolactin and breast Cancer. Front Oncol 2012; 2: 177.
199. Cosgrove L, Shi L, Creasey DE, et al., Antidepressants and breast and ovarian cancer risk: a review of the literature and researchers' financial associations with industry. PLoS One 2011; 6: e18210.
200. Eom CS, Park SM, Cho KH,. Use of antidepressants and the risk of breast cancer: a meta-analysis. Breast Cancer Res Treat 2012; 136: 635-45.
201. Szarfman A, Tonning JM, Levine JG, et al., Atypical antipsychotics and pituitary tumors: a pharmacovigilance study. Pharmacotherapy 2006; 26: 748-58.
202. Hoffer ZS, Roth RL, Mathews M,. Evidence for the partial dopamine-receptor agonist aripiprazole as a first-line treatment of psychosis in patients with iatrogenic or tumorogenic hyperprolactinemia. Psychosomatics 2009; 50: 317-24.
203. Kishimoto T, De Hert M, Carlson HE, et al., Osteoporosis and fracture risk in people with schizophrenia. Curr Opin Psychiatry 2012; 25: 415-29.
204. Stubbs B, De Hert M, Sepehry AA, et al., A meta-analysis of prevalence estimates and moderators of low bone mass in people with schizophrenia. Acta Psychiatr Scand 2014; 130: 470-86.
205. Wu H, Deng L, Zhao L, et al., Osteoporosis associated with antipsychotic treatment in schizophrenia. Int J Endocrinol 2013; 2013: 167138.
206. Tsai K-Y, Lee C-C, Chou Y-M, et al., The risks of major osteoporotic fractures in patients with schizophrenia: a population-based 10-year follow-up study. Schizophr Res 2014; 159: 322-8.
207. Okita K, Kanahara N, Nishimura M, et al., Second-generation antipsychotics and bone turnover in schizophrenia. Schizophr Res 2014; 157: 137-41.
208. Crews MP, Howes OD,. Is antipsychotic treatment linked to low bone mineral density and osteoporosis?. A review of the evidence and the clinical implications. Hum Psychopharmacol 2012; 27: 15-23.
209. Bab IA, Yirmiya R,. Depression and bone mass. Ann NY Acad Sci 2010; 1192: 170-5.
210. Aloumanis K, Mavroudis K,. The "depressive" face of osteoporosis and the "osteoporotic" face of depression. Hormones 2013; 12: 350-62.
211. Cizza G, Primma S, Csako G,. Depression as a risk factor for osteoporosis. Trends Endocrinol Metab 2009; 20: 367-73.
212. Yirmiya R, Bab I,. Major depression is a risk factor for low bone mineral density: a meta-analysis. Biol Psychiatry 2009; 66: 423-32.
213. Cizza G, Primma S, Coyle M, et al., Depression and osteoporosis: a research synthesis with meta-analysis. Horm Metab Res 2010; 42: 467-82.
214. Graham SM, Howgate D, Anderson W, et al., Risk of osteoporosis and fracture incidence in patients on antipsychotic medication. Expert Opin Drug Saf 2011; 10: 575-602.
215. Holt RI,. Osteoporosis in people with severe mental illness: a forgotten condition. Maturitas 2010; 67: 1-2.
216. Seriwatanachai D, Krishnamra N, van Leeuwen JP,. Evidence for direct effects of prolactin on human osteoblasts: inhibition of cell growth and mineralization. J Cell Biochem 2009; 107: 677-85.
217. Woolcott JC, Richardson KJ, Wiens MO, et al., Meta-analysis of the impact of 9 medication classes on falls in elderly persons. Arch Intern Med 2009; 169: 1952-60.
218. Sørensen HJ, Jensen SO, Nielsen J,. Schizophrenia, antipsychotics and risk of hip fracture: a population-based analysis. Eur Neuropsychopharmacol 2013; 23: 872-8.
219. Rigler SK, Shireman TI, Cook-Wiens GJ, et al., Fracture risk in nursing home residents initiating antipsychotic medications. J Am Geriatr Soc 2013; 61: 715-22.
220. Oderda LH, Young JR, Asche CV, et al., Psychotropic-related hip fractures: meta-analysis of first-generation and second-generation antidepressant and antipsychotic drugs. Ann Pharmacother 2012; 46: 917-28.
221. Huang AR, Mallet L, Rochefort CM, et al., Medication-related falls in the elderly: causative factors and preventive strategies. Drugs Aging 2012; 29: 359-76.
222. Hill KD, Wee R,. Psychotropic drug-induced falls in older people: a review of interventions aimed at reducing the problem. Drugs Aging 2012; 29: 15-30.
223. Jalbert JJ, Eaton CB, Miller SC, et al., Antipsychotic use and the risk of hip fracture among older adults afflicted with dementia. J Am Med Dir Assoc 2010; 11: 120-7.
224. Pouwels S, van Staa TP, Egberts AC, et al., Antipsychotic use and the risk of hip/femur fracture: a population-based case-control study. Osteoporos Int 2009; 20: 1499-506.
225. Mehta S, Chen H, Johnson ML, et al., Risk of falls and fractures in older adults using antipsychotic agents: a propensity-matched retrospective cohort study. Drugs Aging 2010; 27: 815-29.
226. Chatterjee S, Chen H, Johnson ML, et al., Risk of falls and fractures in older adults using atypical antipsychotic agents: a propensity score-adjusted, retrospective cohort study. Am J Geriatr Pharmacother 2012; 10: 83-94.
227. Rizzoli R, Cooper C, Reginster JY, et al., Antidepressant medications and osteoporosis. Bone 2012; 51: 606-13.
228. Bruyère O, Reginster JY,. Osteoporosis in patients taking selective serotonin reuptake inhibitors: a focus on fracture outcome. Endocrine 2015; 48: 65-8.
229. Moura C, Bernatsky S, Abrahamowicz M, et al., Antidepressant use and 10-year incident fracture risk: the population-based Canadian Multicentre Osteoporosis Study (CaMoS). Osteoporos Int 2014; 25: 1473-81.
230. Bakken MS, Engeland A, Engesæter LB, et al., Increased risk of hip fracture among older people using antidepressant drugs: data from the Norwegian Prescription Database and the Norwegian Hip Fracture Registry. Age Ageing 2013; 42: 514-20.
231. Rabenda V, Bruyère O, Reginster JY,. Risk of nonvertebral fractures among elderly postmenopausal women using antidepressants. Bone 2012; 51: 674-9.
232. Curtis JR, Yun H, Lange JL, et al., Does medication adherence itself confer fracture protection? An investigation of the healthy adherer effect in observational data. Arthritis Care Res 2012; 64: 1855-63.
233. Vestergaard P, Prieto-Alhambra D, Javaid MK, et al., Fractures in users of antidepressants and anxiolytics and sedatives: effects of age and dose. Osteoporos Int 2013; 24: 671-80.
234. Rabenda V, Nicolet D, Beaudart C, et al., Relationship between use of antidepressants and risk of fractures: a meta-analysis. Osteoporos Int 2013; 24: 121-37.
235. Zucker I, Chodick G, Grunhaus L, et al., Adherence to treatment with selective serotonin reuptake inhibitors and the risk for fractures and bone loss: a population-based cohort study. CNS Drugs 2012; 26: 537-47.
236. Chen F, Hahn TJ, Weintraub NT,. Do SSRIs play a role in decreasing bone mineral density? J Am Med Dir Assoc 2012; 13: 413-7.
237. Wu Q, Bencaz AF, Hentz JG, et al., Selective serotonin reuptake inhibitor treatment and risk of fractures: a meta-analysis of cohort and case-control studies. Osteoporos Int 2012; 23: 365-75.
238. Gagne JJ, Patrick AR, Mogun H, et al., Antidepressants and fracture risk in older adults: a comparative safety analysis. Clin Pharmacol Ther 2011; 89: 880-7.
239. Diem SJ, Blackwell TL, Stone KL, et al., Use of antidepressant medications and risk of fracture in older women. Calcif Tissue Int 2011; 88: 476-84.
240. Davidge Pitts CJ, Kearns AE,. Update on medications with adverse skeletal effects. Mayo Clin Proc 2011; 86: 338-43.
241. Tsapakis EM, Gamie Z, Tran GT, et al., The adverse skeletal effects of selective serotonin reuptake inhibitors. Eur Psychiatry 2012; 27: 156-69.
242. Bliziotes M,. Update in serotonin and bone. J Clin Endocrinol Metab 2010; 95: 4124-32.
243. Misra M, Le Clair M, Mendes N, et al., Use of SSRIs may impact bone density in adolescent and young women with anorexia nervosa. CNS Spectr 2010; 15: 579-86.
244. Verdel BM, Souverein PC, Egberts TC, et al., Use of antidepressant drugs and risk of osteoporotic and non-osteoporotic fractures. Bone 2010; 47: 604-9.
245. van den Brand MW, Pouwels S, Samson MM, et al., Use of anti-depressants and the risk of fracture of the hip or femur. Osteoporos Int 2009; 20: 1705-13.
246. von Heideken Wågert P, Gustafson Y, Kallin K, et al., Falls in very old people: the population-based Umeå 85+study in Sweden. Arch Gerontol Geriatr 2009; 49: 390-6.
247. Abrahamsen B, Brixen K,. Mapping the prescriptiome to fractures in men-a national analysis of prescription history and fracture risk. Osteoporos Int 2009; 20: 585-97.
248. Ginzburg R, Rosero E,. Risk of fractures with selective serotonin-reuptake inhibitors or tricyclic antidepressants. Ann Pharmacother 2009; 43: 98-103.
249. Vestergaard P,. Fracture risks of antidepressants. Expert Rev Neurother 2009; 9: 137-41.
250. Seifert CF, Wiltrout TR,. Calcaneal bone mineral density in young adults prescribed selective serotonin reuptake inhibitors. Clin Ther 2013; 35: 1412-7.
251. Calarge CA, Zimmerman B, Xie D, et al., A cross-sectional evaluation of the effect of risperidone and selective serotonin reuptake inhibitors on bone mineral density in boys. J Clin Psychiatry 2010; 71: 338-47.
252. Wu X, Al-Abedalla K, Rastikerdar E, et al., Selective serotonin reuptake inhibitors and the risk of osseointegrated implant failure: a cohort study. J Dent Res 2014; 93: 1054-61.
253. Hodge JM, Wang Y, Berk M, et al., Selective serotonin reuptake inhibitors inhibit human osteoclast and osteoblast formation and function. Biol Psychiatry 2013; 74: 32-9.
254. Sansone RA, Sansone LA,. SSRIs: bad to the bone? Innov Clin Neurosci 2012; 9: 42-7.
255. Vestergaard P,. Varying effects of psychotropic medications on fracture risk in older people. Evid Based Ment Health 2009; 12: 25.
256. Zamani A, Omrani GR, Nasab MM,. Lithium's effect on bone mineral density. Bone 2009; 44: 331-4.
257. Yang J, Joe SH, Lee MS, et al., Effects of long-term combination treatment with valproate and atypical antipsychotics on bone mineral density and bone metabolism in premenopausal patients with bipolar disorder: a preliminary study. Psychiatry Investig 2011; 8: 256-61.
258. Nurminen J, Puustinen J, Piirtola M, et al., Opioids, antiepileptic and anticholinergic drugs and the risk of fractures in patients 65 years of age and older: a prospective population-based study. Age Ageing 2013; 42: 318-24.
259. Nurminen J, Puustinen J, Piirtola M, et al., Psychotropic drugs and the risk of fractures in old age: a prospective population-based study. BMC Public Health 2010; 10: 396.
260. Baghdady NT, Banik S, Swartz SA, et al., Psychotropic drugs and renal failure: translating the evidence for clinical practice. Adv Ther 2009; 26: 404-24.
261. Raja M,. Lithium and kidney, 60 years later. Curr Drug Saf 2011; 6: 291-303.
262. Tredget J, Kirov A, Kirov G,. Effects of chronic lithium treatment on renal function. J Affect Disord 2010; 126: 436-40.
263. Rej S, Herrmann N, Shulman K,. The effects of lithium on renal function in older adults-a systematic review. J Geriatr Psychiatry Neurol 2012; 25: 51-61.
264. Paul R, Minay J, Cardwell C, et al., Meta-analysis of the effects of lithium usage on serum creatinine levels. J Psychopharmacol 2010; 24: 1425-31.
265. Müller-Oerlinghausen B, Bauer M, Grof P,. Commentary on a recent review of lithium toxicity: what are its implications for clinical practice? BMC Med 2012; 10: 132.
266. Bendz H, Schön S, Attman PO, et al., Renal failure occurs in chronic lithium tratment but is uncommon. Kidney Int 2009; 77: 219-24.
267. Grünfeld J-P, Rossier BC,. Lithium nephrotoxicity revisited. Nat Rev Nephrol 2009; 5: 271-8.
268. International Group for The Study of Lithium Treated Patients. http://www.igsli.org/general-information-on-lithium/adverse-effects-of-lithium-salts.html.
269. Raedler TJ,. Will lithium damage my kidneys? J Psychiatry Neurosci 2012; 37: E5-6.
270. Lerner V, Miodownik C,. Motor symptoms of schizophrenia: is tardive dyskinesia a symptom or side effect? A modern treatment. Curr Psychiatry Rep 2011; 13: 295-304.
271. Correll CU, Leucht S, Kane JM,. Lower risk for tardive dyskinesia associated with second-generation antipsychotics: a systematic review of 1-year studies. Am J Psychiatry 2004; 161: 414-25.
272. Correll CU, Schenk EM,. Tardive dyskinesia and new antipsychotics. Curr Opin Psychiatry 2008; 21: 151-6.
273. Woerner MG, Correll CU, Alvir JM, et al., Incidence of tardive dyskinesia with risperidone or olanzapine in the elderly: results from a 2-year, prospective study in antipsychotic-naïve patients. Neuropsychopharmacology 2011; 36: 1738-46.
274. Pappa S, Dazzan P,. Spontaneous movement disorders in antipsychotic-naive patients with first-episode psychoses: a systematic review. Psychol Med 2009; 39: 1065-76.
275. Ehrenpreis ED, Deepak P, Sifuentes H, et al., The metoclopramide black box warning for tardive dyskinesia: effect on clinical practice, adverse event reporting, and prescription drug lawsuits. Am J Gastroenterol 2013; 108: 866-72.
276. Haddad PM, Dursun SM,. Neurological complications of psychiatric drugs: clinical features and management. Hum Psychopharmacol 2008; 23 (Suppl. 1): 15-26.
277. Ruffmann C, Bogliun G, Beghi E,. Epileptogenic drugs: a systematic review. Expert Rev Neurother 2006; 6: 575-89.
278. Remington G, Agid O, Foussias G, et al., Clozapine and therapeutic drug monitoring: is there sufficient evidence for an upper threshold? Psychopharmacology 2013; 225: 505-18.
279. Young W,. Review of lithium effects on brain and blood. Cell Transplant 2009; 18: 951-75.
280. Leucht S, Burkard T, Henderson J, et al., Physical illness and schizophrenia: a review of the literature. Acta Psychiatr Scand 2007; 116: 317-33.
281. Torniainen M, Mittendorfer-Rutz E, Tanskanen A, et al., Antipsychotic treatment and mortality in schizophrenia. Schizophr Bull 2015; 41: 656-63.
282. Tiihonen J, Suokas JT, Suvisaari JM, et al., Polypharmacy with antipsychotics, antidepressants, or benzodiazepines and mortality in schizophrenia. Arch Gen Psychiatry 2012; 69: 476-83.
283. Cipriani A, Hawton K, Stockton S, et al., Lithium in the prevention of suicide in mood disorders: updated systematic review and meta-analysis. BMJ 2013; 346: f3646.
284. Gibbons RD, Hur K, Brown CH, et al., Relationship between antiepileptic drugs and suicide attempts in patients with bipolar disorder. Arch Gen Psychiatry 2009; 66: 1354-60.